Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06281964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Study acronym: KANNON-2
StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 30, 2026 to Jun 30, 2028 Completion date: Dec 30, 2026 to Jun 30, 2030v5 Show 1 more changeShow less
    • Completion date: Dec 30, 2026 to Jun 30, 2030
  2. Study title revisedv4 See this version in full on ClinicalTrials.gov ↗
  3. Study title revisedv3 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Enrolling by Invitation Study sites: 0 to 1 · Start date changed from estimate of Mar 30, 2024 to Dec 1, 2023 · Eligibility criteria expanded, about 2 wordsv2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 30, 2024 to Dec 1, 2023
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Efficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.
Trial Details
NCT Number NCT06281964
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small-Cell Lung Cancer
Enrollment 327 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov